Zimstat (simvastatin) 5 mg Tablets Shortage and Substitution Approval Extended
Areazine synthesizes this TGA medicine recall directly from TGA's official public data feed. See our methodology for full source attribution and refresh cadence.
The TGA has extended the Serious Scarcity Substitution Instrument for Zimstat 5 mg tablets to address an ongoing supply shortage.
What this TGA medicine recall tells you, and what most readers miss
This notice was issued by TGA on April 6, 2026 and geographically references Australia. Its severity classification of "medium" signals how the issuing agency weighs the risk of harm if no action is taken - "critical" and "high" tier alerts typically carry direct consumer actions, while "medium" and "low" tend toward informational guidance or monitoring advisories. The category it belongs to - Medicine Recalls - determines the consumer-protection framework behind it, which shapes what remedies (refunds, replacements, repairs, or the recall itself) are available to affected consumers and which agency holds statutory responsibility for enforcement.
Most readers skim a notice like this, check whether they are personally affected, and move on. The more useful lens is to verify its scope, source, and timestamp, then compare related notices without assuming that one record proves a broader trend.
Areazine pairs this record with the original agency URL so you can check the primary source before acting. Its related labels are recall, product-safety, tga, Medicine.
What Happened
The Therapeutic Goods Administration (TGA) has announced an extension of the Serious Scarcity Substitution Instrument (SSSI) for Zimstat (simvastatin) 5 mg tablets. This regulatory action was taken in response to an ongoing shortage of the medication to ensure patients can still access treatment.
Which Products Are Affected
The affected product is Zimstat (simvastatin) 5 mg tablets. The shortage pertains to the supply of this specific dosage form within the Australian market.
What You Should Do
Patients who rely on Zimstat 5 mg tablets should consult with their healthcare provider or pharmacist. The extension of the SSSI allows pharmacists to provide a substitute medicine under specific conditions without requiring a new prescription from a doctor, helping to manage the impact of the scarcity.
Why This Matters
This extension is significant as it provides a legal framework for pharmacists to ensure continuity of care for patients requiring simvastatin while the primary brand remains in short supply.
Source
TGA Medicine Shortage Alert - Therapeutic Goods Administration
Original source: TGA Official Notice ↗
Related Medicine Recalls
All Medicine Recalls →Nationwide notices with similar length or severity timing 8
Two Areazine-derived peer sets for this TGA medicine recall: nearest notices by body length and by same severity near the same agency date. Peers come from other categories so they are not the same-feed Related list above.
Similar body length
Nearest notices by article body length (1,308 characters here).
Similar severity timing
Same severity (medium) notices issued closest in time to April 6, 2026.
Frequently Asked Questions
Common questions about this TGA medicine recall.